Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I-infected people with differing clinical status

Yi Ming A. Chen, Shiu Hung Chen, Chong Yau Fu, Jeou Yuan Chen, Mitsuhiro Osame

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Since the presence of anti-p53 antibody has been correlated with the mutation and accumulation of p53, the aim of this study was to detect anti- p53 antibody and understand its correlations with anti-Tof, -Rex, or -Tax antibody reactivity in HTLV-I infected people differing in their clinical status. A plasmid (pGEX-Tof) was constructed to express Tof recombinant protein (RP) in Escherichia coli. Serum samples from 50 asymptomatic carriers (ACs), 50 adult T-cell leukemia (ATL) and 50 MTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients were assayed for reactivity with different RPs by Western immunoblotting. The results showed that 2% of ACs, 4% of ATL patients and 6% of HAM/TSP patients had anti-p53 antibody. Therefore, anti-p53 antibody is not a useful serological marker for clinical management of HTLV-I infected people. Only I HAM/TSP patient had antiTof antibody whose specificity was further confirmed by antibody competition enzyme immunoassay. This study demonstrates that Tof protein is immunogenic in vivo, suggesting that it plays a role in the life cycle and pathogenesis of HTLV-I. The rate of anti-Rex antibody among HAM/TSP patients was significantly higher than that of ACs or ATL patients. In addition, 50% of ACs, 42% of ATL and 98% of HAM/TSP patients had anti-Tax antibody. McNemar's test showed that the presence of anti-p53 antibody did not have any correlation with the anti-Tax antibody in HTLV-I-infected people, while the correlation between anti-p53 and anti-Rex antibodies or anti-p53 and anti- Tof antibodies cannot be ruled out in this study.

Original languageEnglish
Pages (from-to)196-202
Number of pages7
JournalInternational Journal of Cancer
Volume71
Issue number2
DOIs
Publication statusPublished - Jun 27 1997
Externally publishedYes

Fingerprint

Tumor Suppressor Protein p53
Human T-lymphotropic virus 1
Anti-Idiotypic Antibodies
Antibodies
Adult T Cell Leukemia Lymphoma
Tropical Spastic Paraparesis
Antibody Specificity
Spinal Cord Diseases
Life Cycle Stages
Immunoenzyme Techniques
Recombinant Proteins
Plasmids
Biomarkers
Western Blotting
Escherichia coli

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I-infected people with differing clinical status. / Chen, Yi Ming A.; Chen, Shiu Hung; Fu, Chong Yau; Chen, Jeou Yuan; Osame, Mitsuhiro.

In: International Journal of Cancer, Vol. 71, No. 2, 27.06.1997, p. 196-202.

Research output: Contribution to journalArticle

@article{edf98812e48a49dca5c6b4920d7166aa,
title = "Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I-infected people with differing clinical status",
abstract = "Since the presence of anti-p53 antibody has been correlated with the mutation and accumulation of p53, the aim of this study was to detect anti- p53 antibody and understand its correlations with anti-Tof, -Rex, or -Tax antibody reactivity in HTLV-I infected people differing in their clinical status. A plasmid (pGEX-Tof) was constructed to express Tof recombinant protein (RP) in Escherichia coli. Serum samples from 50 asymptomatic carriers (ACs), 50 adult T-cell leukemia (ATL) and 50 MTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients were assayed for reactivity with different RPs by Western immunoblotting. The results showed that 2{\%} of ACs, 4{\%} of ATL patients and 6{\%} of HAM/TSP patients had anti-p53 antibody. Therefore, anti-p53 antibody is not a useful serological marker for clinical management of HTLV-I infected people. Only I HAM/TSP patient had antiTof antibody whose specificity was further confirmed by antibody competition enzyme immunoassay. This study demonstrates that Tof protein is immunogenic in vivo, suggesting that it plays a role in the life cycle and pathogenesis of HTLV-I. The rate of anti-Rex antibody among HAM/TSP patients was significantly higher than that of ACs or ATL patients. In addition, 50{\%} of ACs, 42{\%} of ATL and 98{\%} of HAM/TSP patients had anti-Tax antibody. McNemar's test showed that the presence of anti-p53 antibody did not have any correlation with the anti-Tax antibody in HTLV-I-infected people, while the correlation between anti-p53 and anti-Rex antibodies or anti-p53 and anti- Tof antibodies cannot be ruled out in this study.",
author = "Chen, {Yi Ming A.} and Chen, {Shiu Hung} and Fu, {Chong Yau} and Chen, {Jeou Yuan} and Mitsuhiro Osame",
year = "1997",
month = "6",
day = "27",
doi = "10.1002/(SICI)1097-0215(19970410)71:2<196::AID-IJC12>3.0.CO;2-G",
language = "English",
volume = "71",
pages = "196--202",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof, Rex and Tax in HTLV-I-infected people with differing clinical status

AU - Chen, Yi Ming A.

AU - Chen, Shiu Hung

AU - Fu, Chong Yau

AU - Chen, Jeou Yuan

AU - Osame, Mitsuhiro

PY - 1997/6/27

Y1 - 1997/6/27

N2 - Since the presence of anti-p53 antibody has been correlated with the mutation and accumulation of p53, the aim of this study was to detect anti- p53 antibody and understand its correlations with anti-Tof, -Rex, or -Tax antibody reactivity in HTLV-I infected people differing in their clinical status. A plasmid (pGEX-Tof) was constructed to express Tof recombinant protein (RP) in Escherichia coli. Serum samples from 50 asymptomatic carriers (ACs), 50 adult T-cell leukemia (ATL) and 50 MTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients were assayed for reactivity with different RPs by Western immunoblotting. The results showed that 2% of ACs, 4% of ATL patients and 6% of HAM/TSP patients had anti-p53 antibody. Therefore, anti-p53 antibody is not a useful serological marker for clinical management of HTLV-I infected people. Only I HAM/TSP patient had antiTof antibody whose specificity was further confirmed by antibody competition enzyme immunoassay. This study demonstrates that Tof protein is immunogenic in vivo, suggesting that it plays a role in the life cycle and pathogenesis of HTLV-I. The rate of anti-Rex antibody among HAM/TSP patients was significantly higher than that of ACs or ATL patients. In addition, 50% of ACs, 42% of ATL and 98% of HAM/TSP patients had anti-Tax antibody. McNemar's test showed that the presence of anti-p53 antibody did not have any correlation with the anti-Tax antibody in HTLV-I-infected people, while the correlation between anti-p53 and anti-Rex antibodies or anti-p53 and anti- Tof antibodies cannot be ruled out in this study.

AB - Since the presence of anti-p53 antibody has been correlated with the mutation and accumulation of p53, the aim of this study was to detect anti- p53 antibody and understand its correlations with anti-Tof, -Rex, or -Tax antibody reactivity in HTLV-I infected people differing in their clinical status. A plasmid (pGEX-Tof) was constructed to express Tof recombinant protein (RP) in Escherichia coli. Serum samples from 50 asymptomatic carriers (ACs), 50 adult T-cell leukemia (ATL) and 50 MTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients were assayed for reactivity with different RPs by Western immunoblotting. The results showed that 2% of ACs, 4% of ATL patients and 6% of HAM/TSP patients had anti-p53 antibody. Therefore, anti-p53 antibody is not a useful serological marker for clinical management of HTLV-I infected people. Only I HAM/TSP patient had antiTof antibody whose specificity was further confirmed by antibody competition enzyme immunoassay. This study demonstrates that Tof protein is immunogenic in vivo, suggesting that it plays a role in the life cycle and pathogenesis of HTLV-I. The rate of anti-Rex antibody among HAM/TSP patients was significantly higher than that of ACs or ATL patients. In addition, 50% of ACs, 42% of ATL and 98% of HAM/TSP patients had anti-Tax antibody. McNemar's test showed that the presence of anti-p53 antibody did not have any correlation with the anti-Tax antibody in HTLV-I-infected people, while the correlation between anti-p53 and anti-Rex antibodies or anti-p53 and anti- Tof antibodies cannot be ruled out in this study.

UR - http://www.scopus.com/inward/record.url?scp=0030954219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030954219&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970410)71:2<196::AID-IJC12>3.0.CO;2-G

DO - 10.1002/(SICI)1097-0215(19970410)71:2<196::AID-IJC12>3.0.CO;2-G

M3 - Article

VL - 71

SP - 196

EP - 202

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -